Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15300449 | 0.87 | KMT2A (0.53) | HPGDKMT2AGAASMN1; SMN2APEX1 | |
| SCHEMBL16658357 | 0.82 | HPGD (0.69) | HPGDKMT2APKMGAAL3MBTL1 | |
| SCHEMBL29092475 | 0.82 | KMT2A (0.69) | HPGDKMT2APKMGAAL3MBTL1 | |
| SCHEMBL28053361 | 0.82 | APEX1 (0.57) | HPGDKMT2APKMGAAL3MBTL1 | |
| SCHEMBL11319016 | 0.81 | KMT2A (0.69) | HPGDKMT2AGAAL3MBTL1LMNA | |
| SCHEMBL20145424 | 0.79 | KMT2A (0.74) | HPGDKMT2APKMGAAL3MBTL1 | |
| SCHEMBL1500192 | 0.79 | HPGD (0.74) | HPGDKMT2APKMGAAL3MBTL1 | |
| SCHEMBL20145565 | 0.79 | HPGD (0.74) | HPGDKMT2APKMGAAL3MBTL1 | |
| SCHEMBL21296316 | 0.79 | NPC1 (0.59) | HPGDKMT2AAPEX1MEN1ALDH1A1 | |
| SCHEMBL16651061 | 0.79 | HPGD (0.70) | HPGDKMT2AL3MBTL1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3755689-B1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11584746-B2 | Inhibitors of EGFR and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584746-B2 | Inhibitors of EGFR and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210085688-A1 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20210085688-A1 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20210040088-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20210040088-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2021-02-11 | — | — | US | disclosed |
| EP-3755338-A1 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3755690-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3755689-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200390783-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200377501-A1 | DEGRADERS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377501-A1 | DEGRADERS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200375999-A1 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200375999-A1 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377477-A1 | DEGRADERS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377477-A1 | DEGRADERS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2019164941-A1 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019164947-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019164948-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200375999-A1 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB3, ERBB2 | HPGD 2793/4885KMT2A 4564/4885PKM 3249/4885 |
| US-20210040088-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | HPGD 2073/4885KMT2A 4667/4885PKM 3228/4885 |
| US-11584746-B2 | Inhibitors of EGFR and methods of use thereof | EGFR, ERBB2, ERBB3 | HPGD 2073/4885KMT2A 4667/4885PKM 3228/4885 |
| US-20200377501-A1 | DEGRADERS OF EGFR AND METHODS OF USE THEREOF | EGFR, CRBN, CBL | HPGD 3881/4885KMT2A 3153/4885PKM 4094/4885 |
| US-20210085688-A1 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB3, ERBB2 | HPGD 2755/4885KMT2A 4477/4885PKM 3085/4885 |
| US-20200390783-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | HPGD 1900/4885KMT2A 4735/4885PKM 3678/4885 |
| US-20200377477-A1 | DEGRADERS OF EGFR AND METHODS OF USE THEREOF | EGFR, CRBN, CBL | HPGD 4024/4885KMT2A 2536/4885PKM 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.